The need for cold-chain transportation has been a prominent barrier in making vaccines available to developing countries. A consortium led by Mymetics' Dutch subsidiary has just received €8.4 million to change that.
With a brand-new $156 million Gates Foundation grant in hand, the PATH Malaria Vaccine Initiative has signed on Switzerland-based Mymetics to develop and produce virosome-based vaccine formulations for a malaria transmission-blocking vaccine candidate.
A pair of Dendreon veterans has swooped in to take charge of the troubled Swiss biotech Mymetics with ambitious plans.
Switzerland's Mymetics says that its experimental malaria vaccine could be ready for marketing as early as 2014. CEO Christain Rochet says that clinical trials on the vaccine--obtained from